The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

Conclusion: Oral semaglutide+metformin seems not cost effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.PMID:34841893 | DOI:10.2217/cer-2021-0169

Source: Journal of Comparative Effectiveness Research - November 29, 2021 Category: General Medicine Authors: Lars H Ehlers Mark Lamotte Mafalda C Ramos Susanne Sandgaard Pia Holmgaard Evan C Frary Niels Ejskjaer Source Type: research